OMN-6 is under clinical development by Omnix Medical and currently in Phase I for Ventilator Associated Pneumonia (VAP). According to GlobalData, Phase I drugs for Ventilator Associated Pneumonia (VAP) have an 83% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how OMN-6’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
OMN-6 overview
OMN-6 is under development for the treatment of multi-drug resistant Acinetobacter baumannii infections, hospital associated bacterial pneumoniae (HABP/VABP), blood-stream infections (BSI) and complicated urinary-tract infections (cUTI). It is administered through intravenous route. It acts by targeting bacterial membrane. The drug candidate is being developed based company’s technology which utilizes biochemical engineering to enable the synthesis of soluble, stable, safe and highly-potent antimicrobial-peptides.
See Also:
Omnix Medical overview
Omnix Medical is a biopharmaceutical company that develops an arsenal of novel antibiotic agents for the treatment of infections involving drug-resistant bacteria. The company’s pipeline includes three programs such as OMN6 targeting Gram-negative bacteria, OMN-51 a new antimicrobial peptide (AMP) targeting Gram-negative bacteria like P. aeruginosa, and OMN-71 a antimicrobial peptide (AMP) targeting bacteria involved with skin infections in patients with Atopic-Dermatitis or Acne. Omnix Medical is headquartered in Jerusalem, Israel.
For a complete picture of OMN-6’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
